EpimAb Biotherapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Develops bispecific antibodies for cancer and immunology using its proprietary FIT-Ig platform.
OncologyImmunology
Technology Platform
Proprietary FIT-Ig platform for the efficient design and development of native IgG-like bispecific antibodies.
Opportunities
Leveraging its versatile platform to address high-value targets in immuno-oncology and autoimmune diseases through partnerships and internal programs.
Risk Factors
Clinical and commercial competition in bispecifics is intense, requiring clear differentiation in efficacy or safety.
Competitive Landscape
A leading bispecific antibody player in China, competing with global biologics giants and specialized platform companies.